MedTrace Logo

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects

NCT07229716 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-27

No results posted yet for this study

Summary

This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.

Conditions

Interventions

DRUG

HRS-9813 Capsule

HRS-9813 capsule, specified dose on specified days.

DRUG

Nintedanib Soft Capsules

Nintedanib soft capsules, specified dose on specified days.

DRUG

Pirfenidone Tablets

Pirfenidone tablets, specified dose on specified days.

Sponsors & Collaborators

  • Guangdong Hengrui Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-04
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07229716 on ClinicalTrials.gov